ArriVent lung cancer drug fails Phase 3 trial

Statements (3)

1. ▼ Bearish

   ArriVent's value decreased by more than half following disappointing lung cancer data

   biopharmadive.comOct 6, 2026 16:12 UTCHigh importance
2. ▼ Bearish

   ArriVent BioPharma's lung cancer drug firmonertinib failed a Phase 3 trial

   endpoints.newsOct 6, 2026 14:47 UTCHigh importance
3. ▼ Bearish

   ArriVent's lung cancer treatment failed in a late-stage trial

   reuters.comOct 6, 2026 12:19 UTCHigh importance